Table 2 Transition probability parameters

From: Cost-utility and budget impact analyses of anaplastic lymphoma kinase inhibitors in Thailand

Transition probability

Probabilities of disease progression

Probabilities of death

Mean

SE

Source

Mean

SE

Source

Brigatinib 1 st – 5th month

0.0109

0.00057

39

0.0065

0.00033

39

Brigatinib 6th - 10th month

0.0067

0.00037

39

0.0065

0.00033

39

Brigatinib 11th - 15th month

0.0057

0.00032

39

0.0130

0.00066

39

Brigatinib 16th - 20th month

0.0034

0.00017

39

0.0065

0.00033

39

Brigatinib 21 st - 30th month onward

0.0159

0.00083

39

0.0445

0.00227

39

Ceritinib 1 st – 5th month

0.0296

0.00151

38

0.0075

0.00038

38

Ceritinib 6th - 10th month

0.0193

0.00098

38

0.0075

0.00038

38

Ceritinib 11th - 15th month

0.0164

0.00084

38

0.0149

0.00076

38

Ceritinib 16th - 20th month

0.0090

0.00046

38

0.0075

0.00038

38

Ceritinib 21 st - 30th month onward

0.0426

0.00217

38

0.0511

0.00261

38

Alectinib 1 st – 5th month

0.0098

0.00050

39

0.0033

0.00017

39

Alectinib 6th - 10th month

0.0064

0.00033

39

0.0033

0.00017

39

Alectinib 11th - 15th month

0.0054

0.00028

39

0.0066

0.00034

39

Alectinib 16th - 20th month

0.0030

0.00015

39

0.0033

0.00017

39

Alectinib 21 st - 30th month onward

0.0140

0.00071

39

0.0225

0.00115

39

Carboplatin plus paclitaxel

0.1139

0.00581

40

0.0392

0.00168

40

Pemetrexed plus cisplatin/carboplatin

0.0316

0.00161

16

0.0130

0.00156

16

Gemcitabine plus cisplatin/carboplatin

0.0683

0.00348

41

0.0350

0.00179

41

Docetaxel

0.0571

0.00135

42

0.0464

0.00214

42

BSC

-

-

-

0.0494

0.00252

43

  1. Abbreviations: BSC, best supportive care; THB, Thai baht; USD, United States dollar; SE, standard error of the mean.
Back to article page